Pharmaceutical Industry Today

Preclinical Oncology Models Market Size, Share and Trends Analysis to 2031

"Global Preclinical Oncology Models Market– By Product Type (Patient-Derived Xenograft Models (PDX), Cell Line Derived Xenograft Models, Syngeneic Models, Genetically engineered mouse models (GEMMs), Orthotopic Models, Custom Xenograft and Syngeneic Model) - Global Forecast to 2030" The report features detailed industry analysis and extensive insights on the market, exploring its significant growth factors.
Published 19 December 2023

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on "Global Preclinical Oncology Models Market– By Product Type (Patient-Derived Xenograft Models (PDX), Cell Line Derived Xenograft Models, Syngeneic Models, Genetically engineered mouse models (GEMMs), Orthotopic Models, Custom Xenograft and Syngeneic Model) - Global Forecast to 2030"  The report features detailed industry analysis and extensive insights on the market, exploring its significant growth factors.

According to the latest market intelligence research report by InsightAce Analytic, the global preclinical oncology models market size was valued at US$ 1,020.2 Million in 2021, and it is expected to reach US$ 2,463.7 Million in 2030, recording a promising CAGR of 10.6% from 2022 to 2030.

Request Sample Report: https://www.insightaceanalytic.com/request-sample/1093

Scientists require preclinical oncology models to predict the clinical efficacy of novel anticancer drugs. The increased demand for cancer immunotherapy has spawned numerous preclinical and translational obstacles. Therefore, there is an excellent need for preclinical models to screen anticancer agents with solid clinical correlation accurately.

Advances in immuno-oncology, increasing targeted and novel cancer therapies, rising R&D activities in oncology and drug development, high demand for robust preclinical oncology models such as humanized and syngeneic tumour models, and the rising need to reduce translational failures in clinical trials are anticipated to drive market growth during the forecast period. In addition, the need for the rational design of combination therapies and the early identification of predictive biomarkers also contribute to expanding the preclinical oncology models market.

Preview for Detailed TOC: https://www.insightaceanalytic.com/report/global-preclinical-oncology-models-market/1093

 The prominent players in the preclinical oncology models industry include:

Aragen Bioscience, vivoPharm Pty. Ltd. Bioduro, Crown Bioscience Inc., Charles River, Champion Oncology, Inc., Envigo, GenOway S.A., Hera BioLabs, MI Bioresearch Inc, Pharmatest Services, Taconic Biosciences, Inc., The Jackson Laboratory, and Other Prominent Players.

Key Industry Developments from Leading Players:

  • In Dec 2021, Crown Bioscience, a leading contract research organization (CRO) in preclinical and translational drug development services, expanded its Crown Bioscience United Kingdom facility. This expansion offers additional imaging modalities to visualize better and understand tumor progression and response to potential therapies. The additional imaging platform allows performing cutting-edge preclinical studies, offering advanced insights on potential drug candidates before clinical trials.
  • In Feb 2021, Charles River Laboratories International, Inc. partnered with Kibur Medical to provide exclusive access to its implantable microdevice (IMD) for in vivo preclinical oncology studies.
  • In May 2020, BioDuro, LLC, a leading drug discovery and development services organization, announced the availability of two new preclinical models for Non-alcoholic steatohepatitis (NASH) that highly resemble the clinical progression of the disease. The models include mouse and hamster species and manifest all the hallmarks of NASH disease, enabling drug developers to evaluate broad classes of drug targets, including metabolic inflammation and fibrogenic pathways alike.

Preclinical Oncology Models Market Regional Analysis:

North America is expected to be the most lucrative region of this market in the forecast years, owing to the high demand for cancer immunotherapies, increasing research funding for oncology, and the need for preclinical oncology models.

The Asia Pacific is estimated to proliferate during the analysis of the forecast period. The technological advancement in cancer diagnostic techniques & treatment, high demand for targeted therapies, and the increasing R&D initiatives in oncology clinical trials by industry players are the factors responsible for the regional market growth.

Inquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1093

The Global Preclinical Oncology Models Market Segments

The Global Preclinical Oncology Models Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2019 to 2030 based on Product

·      Patient-Derived Xenograft Models (PDX)

·      Cell Line Derived Xenograft Models

·      Syngeneic Models

·      Genetically engineered mouse models (GEMMs)

·      Orthotopic Models

·      Custom Xenograft and Syngeneic Model

·      Others

The Global Preclinical Oncology Models Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2019 to 2030 based on Application

·      Neuroblastoma

·      Prostate Cancer

·      Pancreatic Cancer

·      Breast Cancer

·      Colorectal Cancer

·      Bladder Cancer

·      Fibrosarcoma

·      Kidney Cancer

·      Liver Cancer

·      Lung Cancer

·      Lymphoma

·      Skin Cancer

·      Others

The Global Preclinical Oncology Models Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2019 to 2030 based on Region

  • Europe
  • North America
  • Latin America
  • Asia Pacific
  • Middle East & Africa

North America Preclinical Oncology Models Market Estimates Revenue (US$ Million) by Country, 2019 to 2030

  • U.S.
  • Canada

Europe Preclinical Oncology Models Market Estimates Revenue (US$ Million) by Country, 2019 to 2030

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Preclinical Oncology Models Market Estimates Revenue (US$ Million) by Country, 2019 to 2030

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Preclinical Oncology Models Market Estimates Revenue (US$ Million) by Country, 2019 to 2030

  • Brazil
  • Mexico
  • Rest of Latin America

The Middle East & Africa Preclinical Oncology Models Market Estimates Revenue (US$ Million) by Country, 2019 to 2030

  • GCC Countries
  • South Africa
  • Rest of the Middle East & Africa

For Customized Information @ https://www.insightaceanalytic.com/customisation/1093

Other Related Reports Published by InsightAce Analytic:

Global Immuno-Oncology Cell Therapy Market

Global CAR T-Cell Therapy For Multiple Myeloma Market

Global Oncolytic Virus Therapy Market

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact Us:

Priyanka Tilekar

InsightAce Analytic Pvt. Ltd.

Visit: www.insightaceanalytic.com

Tel : +1 551 226 6109

Asia: +91 79 72967118

Email: info@insightaceanalytic.com

Follow Us on LinkedIn @ bit.ly/2tBXsgS

Follow Us On Facebook @ bit.ly/2H9jnDZ

Other Industry News

Ready to start publishing

Sign Up today!